A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week; or interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
Inclusion Criteria:
Exclusion Criteria:
New York, New York 63110, United States
Ciudad de Buenos Airesa, C1013AAB, Argentina
Lommé, 59462, France
München, 81675, Germany
Ulm, 89073, Germany
Torrette - Ancona, The Marches 60100, Italy
Guadalajara, Jalisco 44620, Mexico
Chihuahua City, 31238, Mexico
Lodz, 90-153, Poland
Olsztyn, 10-561, Poland
Siemianowice ?l?skie, 41-100, Poland
Barnaul, Altayskiy Kray 656024, Russia
Saint Petersburg, Sankt-Peterburg 197022, Russia
Kazan', Tatarstan Republic 420101, Russia
Nizniy Novgorod, 603155, Russia
L'Hospitalet de Llobregat, Barcelona 08907, Spain
Istanbul, 34098, Turkey (Türkiye)
Donetsk, 83045, Ukraine